Vanda Pharmaceuticals enters the post-Q1 stretch having just delivered a messy earnings print — but with a guidance raise that gives the bulls something to work with.
The company reported Q1 EPS of -$0.82, missing the -$0.69 consensus by $0.13. Revenue of $51.7M fell short of the $55.0M estimate. Those are not trivial misses. Yet Vanda simultaneously raised full-year 2026 sales guidance to $240M–$290M, widening the range but lifting both ends above the previous $230M–$260M band. The catalyst is clear: NEREUS (tradipitant), commercially launched in the US on May 4 — the first new pharmacologic treatment for motion sickness in over 40 years — has arrived on shelves, and management is betting it moves the revenue needle.
Short positioning heading into that result had been building meaningfully. Short interest climbed 66% over the past month to 9.6% of the free float — a real number for a small biotech. The bulk of that build happened in mid-April, when shorts jumped from roughly 3.4M shares to 5.2M shares in a single week. Since that spike, the position has barely moved; shorts trimmed just 1.4% over the past week and are essentially sitting on their bet. Borrowing conditions give them little friction to maintain it: cost to borrow is a negligible 0.56%, and availability remains ample, meaning the lending market is not putting pressure on the short side to cover.
Options tell a different story at the margin. The put/call ratio has drifted higher than its recent average, with the current reading of 0.12 running about 1.6 standard deviations above the 20-day mean of 0.10. That is a mild uptick in downside hedging — not a panic signal given how low both numbers are in absolute terms, but directionally it suggests some options participants were buying protection into the earnings event.
The Street is constructively positioned but the analyst data carries some staleness. The most recent formal coverage initiation was Truist Securities in early March, coming in with a Buy and an $18 target. HC Wainwright has been the loudest bull, lifting its target twice in late 2025 and into early 2026 to reach $24. On the other end, Jefferies held a Hold with a $7.50 target raised from $5. With the stock at $7.39, the mean analyst target of $15.50 implies a wide gap — but it's worth noting the consensus reflects data from March and earlier, before the Q1 miss was known. The Jefferies target, sitting just above the current price, may prove the more relevant near-term anchor.
Ownership adds another layer of texture. The top holder is BlackRock at nearly 13% of shares. Aigh Capital Management added 751,569 shares in the most recent quarter to reach 4.6% — a notable conviction add from a specialist manager. State Street's last reported change was a 1.8M share addition, the single largest quarterly move among the top holders. On the insider side, March 2 saw a coordinated sell across the executive suite: the CEO, CFO, CMO, General Counsel, and a Senior VP all sold on the same day at around $8.26, collectively moving over $2.5M in stock. That cluster sale — all at a price above where the stock trades today — is worth watching as context for how insiders viewed valuation at the time relative to current levels.
The next earnings event is set for June 4. Between now and then, the key question is whether early NEREUS sell-through data supports the top end of the raised guidance range — or whether the Q1 revenue miss reflects structural commercial drag that the new launch cannot quickly offset. The short book is large enough to be sensitive to either outcome.
See the live data behind this article on ORTEX.
Open VNDA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
